Financial Results for the First Half of
Fiscal Year Ending March 31, 2022 (FY2021)

from the beginning

Financial Results for the First Half of Fiscal Year Ending March 31, 2022 (FY2021)

• Safe Harbor for Forward-Looking Statements and Use of Document

• Highlights

• P&L Results

• Adjusted Operating Profit Variance Analysis (Q2 YTD)

• Adjusted Operating Profit Variance Analysis (Q2)

• Revenue by Region

• C&V

• GH

• TBCT

• Upward Revision of Dividend Forecast

• Major Topics

Reference

• FY21 New Product Pipeline

• Revenue by Segment and Region

• Quarterly Trend of Revenue and Operating Profit

• P&L (Quarterly Results)

• Operating Expenses (Quarterly Results)

• Operating Expenses (YTD and Quarterly Results)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q2 YTD)

• Cash Flows (Q2)

• Foreign Exchange Sensitivity

@

A New Stage in US Market Strategy:Utilize M&A to further build capability and expand presence

• Safe Harbor for Forward-Looking Statements and Use of Document

• TA Achieves Full Lineup of Aortic Products in the US

• Growth of US Business &Acquisitions (from 2000)

• 20 Years of C&V Business in the US Market

• Improved Status in the US

• Trajectory of Sustainable Growth Centered on Acquisitions outside Japan

• Management Capability, Value Chain Evolution

• US market Growth Potential in GS26

• Potential in the US to Expand Solution Business

• Era of Fully Leveraging Overall Group Strengths

@